Abdelwahab Hashem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdelwahab Hashem has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Mahmoud Laymon
Urology Department, Urology and Nephrology Center, Mansoura, Egypt
7 shared publicationsAhmed Mosbah
Affiliation Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
6 shared publicationsTamer E. Helmy
Pediatric Urology Department, Urology and Nephrology Center, Mansoura, Egypt
6 shared publicationsKhaled Z. Sheir
Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
5 shared publications- Ahmed Abdelhalim
Department of Urology, Mansoura Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
4 shared publications - Ahmed Mohamed Elshal
Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
4 shared publications
Latest Publications
- 19 March 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (6)
Correlation between post-pyeloplasty diuretic scintigraphic and ultrasonographic parameters in children
- 19 March 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (6)
Correlation between post-pyeloplasty diuretic scintigraphic and ultrasonographic parameters in children
- Open Access
- 23 December 2025
- Published by Springer Nature in Current Urology Reports
- Vol. 27 (1) , 1
Bladder Neck Incision in Posterior Urethral Valve Management: a Meta-Analysis with Insights into Adjunctive Bladder Interventions
Purpose of Review: To evaluate the outcomes of bladder neck incision (BNI) and alternative treatments, such as alpha blockers, in improving voiding dysfunction in posterior urethral valve (PUV) after valve ablation (VA). Recent Findings: Eleven studies comprising 826 patients with PUV were included. Concomitant BNI and VA significantly improved both VUR resolution (Risk Ratio “RR”= 1.36; 95% CI: 1.04–1.79), and postoperative serum creatinine -0.16 (95% CI: -0.28 to -0.04). Concomitant BNI and VA significantly improved detrusor overactivity (RR = 0.44; 95% CI: 0.22–0.91; p = 0.03), and reduced significantly maximum detrusor pressure at Qmax (Pdetmax) by-23.53 (95% CI: -35.01 to -12.05). It also significantly decreased both the use of alpha blocker/anticholinergic (RR = 0.59; 95% CI: 0.36 to 0.95), and the need for intermittent catheterization (RR = 0.16; 95% CI: 0.03 to 0.83; p = 0.03). However, there were no significant difference either in bladder compliance (RR = 0.75; 95% CI: 0.31 to 1.79), nor children required re-intervention (RR = 0.52; 95% CI: 0.25 to 1.05). Alpha blockers after VA showed a pooled post-void residual urine reduction of -59.44 (95% CI: -129.05 to 10.17). The pooled estimate for peak flow rate with alpha blockers was 14.22 (95% CI: 13.70–14.74). Summary: BNI combined with valve ablation could improves bladder function and reduces the need for additional interventions compared to VA alone.
- 23 December 2025
- Published by Springer Nature in Current Urology Reports
- Vol. 27 (1) , 1
Open AccessBladder Neck Incision in Posterior Urethral Valve Management: a Meta-Analysis with Insights into Adjunctive Bladder Interventions
Purpose of Review: To evaluate the outcomes of bladder neck incision (BNI) and alternative treatments, such as alpha blockers, in improving voiding dysfunction in posterior urethral valve (PUV) after valve ablation (VA). Recent Findings: Eleven studies comprising 826 patients with PUV were included. Concomitant BNI and VA significantly improved both VUR resolution (Risk Ratio “RR”= 1.36; 95% CI: 1.04–1.79), and postoperative serum creatinine -0.16 (95% CI: -0.28 to -0.04). Concomitant BNI and VA significantly improved detrusor overactivity (RR = 0.44; 95% CI: 0.22–0.91; p = 0.03), and reduced significantly maximum detrusor pressure at Qmax (Pdetmax) by-23.53 (95% CI: -35.01 to -12.05). It also significantly decreased both the use of alpha blocker/anticholinergic (RR = 0.59; 95% CI: 0.36 to 0.95), and the need for intermittent catheterization (RR = 0.16; 95% CI: 0.03 to 0.83; p = 0.03). However, there were no significant difference either in bladder compliance (RR = 0.75; 95% CI: 0.31 to 1.79), nor children required re-intervention (RR = 0.52; 95% CI: 0.25 to 1.05). Alpha blockers after VA showed a pooled post-void residual urine reduction of -59.44 (95% CI: -129.05 to 10.17). The pooled estimate for peak flow rate with alpha blockers was 14.22 (95% CI: 13.70–14.74). Summary: BNI combined with valve ablation could improves bladder function and reduces the need for additional interventions compared to VA alone.
- Open Access
- 6 July 2025
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 19 (1) , 1-22
Robotic-assisted ureteroenteric reimplantation for ureteroenteric stricture after radical cystectomy: a systematic review and dual meta-analysis
Background and Objective: Benign ureteroenteric stricture (UES) is a well-documented long-term complication that can occur after radical cystectomy with urinary diversion (UD). This meta-analysis evaluates the safety and feasibility of Robotic-assisted Ureteroenteric Reimplantation (RUER), with a focus on distinguishing outcomes between Open Ureteroenteric Reimplantation (OUER) and RUER. Methods: We performed an extensive search across multiple databases, including PubMed, Scopus, and Web of Science, to identify studies that assessed outcomes for RUER alone or in comparison to OUER. Relevant data were systematically extracted and recorded in an Excel sheet. Data analysis was performed using OpenMeta [Analyst] and Review Manager Software. Results: This review included 277 UES patients (244 RUER, 33 OUER) with 289 and 35 reimplantations, respectively. RUER had 91.7% success rate and a 7.1% stricture recurrence rate. Intraoperative complications, Clavien-Dindo ≥3 complications, conversion to open approach, and hospital readmission rates were 2.3%, 9.5%, 2.5%, and 7.8%, respectively. Compared to OUER, RUER showed similar success (RR =1.01, p=0.83) and stricture recurrence rates (RR = 0.89, p=0.72) but significantly lower intraoperative (RR =0.13, p=0.01), postoperative (RR = 0.53, p = 0.004), and Clavien-Dindo ≥3 complications (RR =0.27, p =0.01). RUER significantly reduced hospital stay (MD = -3.18 days, p = 0.0002) but showed no significant reduction in operative time (MD= -24.98 min, p=0.29). Conclusions: RUER offers comparable success to OUER with significantly lower complication rates and shorter hospital stays, making it a safe and feasible minimally invasive alternative for strictures ranging from 1 to 3 cm.
- 6 July 2025
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 19 (1) , 1-22
Open AccessRobotic-assisted ureteroenteric reimplantation for ureteroenteric stricture after radical cystectomy: a systematic review and dual meta-analysis
Background and Objective: Benign ureteroenteric stricture (UES) is a well-documented long-term complication that can occur after radical cystectomy with urinary diversion (UD). This meta-analysis evaluates the safety and feasibility of Robotic-assisted Ureteroenteric Reimplantation (RUER), with a focus on distinguishing outcomes between Open Ureteroenteric Reimplantation (OUER) and RUER. Methods: We performed an extensive search across multiple databases, including PubMed, Scopus, and Web of Science, to identify studies that assessed outcomes for RUER alone or in comparison to OUER. Relevant data were systematically extracted and recorded in an Excel sheet. Data analysis was performed using OpenMeta [Analyst] and Review Manager Software. Results: This review included 277 UES patients (244 RUER, 33 OUER) with 289 and 35 reimplantations, respectively. RUER had 91.7% success rate and a 7.1% stricture recurrence rate. Intraoperative complications, Clavien-Dindo ≥3 complications, conversion to open approach, and hospital readmission rates were 2.3%, 9.5%, 2.5%, and 7.8%, respectively. Compared to OUER, RUER showed similar success (RR =1.01, p=0.83) and stricture recurrence rates (RR = 0.89, p=0.72) but significantly lower intraoperative (RR =0.13, p=0.01), postoperative (RR = 0.53, p = 0.004), and Clavien-Dindo ≥3 complications (RR =0.27, p =0.01). RUER significantly reduced hospital stay (MD = -3.18 days, p = 0.0002) but showed no significant reduction in operative time (MD= -24.98 min, p=0.29). Conclusions: RUER offers comparable success to OUER with significantly lower complication rates and shorter hospital stays, making it a safe and feasible minimally invasive alternative for strictures ranging from 1 to 3 cm.
- Open Access
- 18 January 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Tunica vaginalis or dartos as second layer coverage for distal and mid-shaft penile hypospadias, quo vadis?
Purpose: To compare between the dartos and tunica vaginalis flaps as covering layers in denovo distal or mid-shaft penile hypospadias underwent tubularized incised plate (TIP) repair. Methods: This is a single-center, randomized trial was for denovo distal or mid-shaft penile hypospadias. Children with history of orchiectomy, orchiopexy and inguinal hernia repair were excluded. Eighty-eight patients were divided into two groups: the first used dartos flap (DF), while the second used tunica vaginalis flap (TVF). The primary outcome was to assess the incidence of urethrocutaneous fistula. The secondary outcome was to assess cosmetic outcome using paediatric penile perception score (PPPS) and hypospadias objective scoring evaluation (HOSE). Results: Baseline demographic and clinical characteristics showed no statistically significant. Median operative time (IQR) was 100 (90, 120) and 145 (140, 150) minutes in in DF and TVF Groups, respectively (p < 0.001). Urethrocutaneous Fistula was detected in 9 (20.9%) in DF group and 2 (4.9%) in TVF group (p 0.029). Meatal stenosis occurred in 3 (7%) in DF group and 2 (4.9%) in TVF group. Penile torque was diagnosed in one (2.4%) in TVF group. There was no significant difference in total PPPS score (p = 0.076), however, there was a significant difference in total HOSE score in the favour to TVF group (p = 0.024). At 12 months, testicular ascent occurred in 0% and 3 (7.3%) in DF and TVF groups, respectively (p = 0.071). Conclusion: Compared to dartos flap, tunica vaginalis flap significantly helps in reduction of fistula rate. However, it has significant more operative time.
- 18 January 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Open AccessTunica vaginalis or dartos as second layer coverage for distal and mid-shaft penile hypospadias, quo vadis?
Purpose: To compare between the dartos and tunica vaginalis flaps as covering layers in denovo distal or mid-shaft penile hypospadias underwent tubularized incised plate (TIP) repair. Methods: This is a single-center, randomized trial was for denovo distal or mid-shaft penile hypospadias. Children with history of orchiectomy, orchiopexy and inguinal hernia repair were excluded. Eighty-eight patients were divided into two groups: the first used dartos flap (DF), while the second used tunica vaginalis flap (TVF). The primary outcome was to assess the incidence of urethrocutaneous fistula. The secondary outcome was to assess cosmetic outcome using paediatric penile perception score (PPPS) and hypospadias objective scoring evaluation (HOSE). Results: Baseline demographic and clinical characteristics showed no statistically significant. Median operative time (IQR) was 100 (90, 120) and 145 (140, 150) minutes in in DF and TVF Groups, respectively (p < 0.001). Urethrocutaneous Fistula was detected in 9 (20.9%) in DF group and 2 (4.9%) in TVF group (p 0.029). Meatal stenosis occurred in 3 (7%) in DF group and 2 (4.9%) in TVF group. Penile torque was diagnosed in one (2.4%) in TVF group. There was no significant difference in total PPPS score (p = 0.076), however, there was a significant difference in total HOSE score in the favour to TVF group (p = 0.024). At 12 months, testicular ascent occurred in 0% and 3 (7.3%) in DF and TVF groups, respectively (p = 0.071). Conclusion: Compared to dartos flap, tunica vaginalis flap significantly helps in reduction of fistula rate. However, it has significant more operative time.
- Open Access
- 30 December 2024
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 23 (4) , 294-300
Fluoxetine, a selective serotonin reuptake inhibitor, versus desmopressin in primary monosymptomatic nocturnal enuresis: A randomised controlled trial
To evaluate the efficacy of fluoxetine 20 mg, a selective serotonin reuptake inhibitor, versus the standard treatment, desmopressin 0.2 mg, in primary monosymptomatic nocturnal enuresis (PMNE) treatment. This was a single-blinded randomized controlled clinical trial. Children ≥7 years old on urotherapy and who still had severe PMNE were screened for eligibility. Children were maintained on 20 mg of fluoxetine or desmopressin 0.2 mg orally once daily for 3 months. The primary outcome for this trial was to assess the efficacy of both drugs as quantified by the change from baseline in the frequency of nocturnal enuresis at three months. The secondary endpoints were treatment-related side effects and nighttime arousal. The baseline parameters were comparable between both groups. The response to treatment at 1 month as non-responders (NR), partial responders (PR), and complete responders (CR) was 69%, 24.1%, and 6.9% versus 57.1%, 32.1%, and 10.7% in fluoxetine and desmopressin groups, respectively (p = 0.65). At the third month, the NR, PR, and CR were 69%, 31%, and 0% versus 57.1%, 32.1%, and 10.7% in fluoxetine and desmopressin groups, respectively (p = 0.18). Nighttime arousal was better in the fluoxetine group (41.4%) versus 14.3% in the desmopressin group, p = 0.02, at the first month, and it decreased to 31% in the fluoxetine group versus 14.3% in the desmopressin group, p = 0.13, at the third month. Fluoxetine 20 mg, a selective serotonin reuptake inhibitor, is non-inferior to desmopressin 0.2 mg for the management of PMNE. Fluoxetine improves nighttime arousal significantly at the first month. This improvement becomes insignificant at the third month.
- 30 December 2024
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 23 (4) , 294-300
Open AccessFluoxetine, a selective serotonin reuptake inhibitor, versus desmopressin in primary monosymptomatic nocturnal enuresis: A randomised controlled trial
To evaluate the efficacy of fluoxetine 20 mg, a selective serotonin reuptake inhibitor, versus the standard treatment, desmopressin 0.2 mg, in primary monosymptomatic nocturnal enuresis (PMNE) treatment. This was a single-blinded randomized controlled clinical trial. Children ≥7 years old on urotherapy and who still had severe PMNE were screened for eligibility. Children were maintained on 20 mg of fluoxetine or desmopressin 0.2 mg orally once daily for 3 months. The primary outcome for this trial was to assess the efficacy of both drugs as quantified by the change from baseline in the frequency of nocturnal enuresis at three months. The secondary endpoints were treatment-related side effects and nighttime arousal. The baseline parameters were comparable between both groups. The response to treatment at 1 month as non-responders (NR), partial responders (PR), and complete responders (CR) was 69%, 24.1%, and 6.9% versus 57.1%, 32.1%, and 10.7% in fluoxetine and desmopressin groups, respectively (p = 0.65). At the third month, the NR, PR, and CR were 69%, 31%, and 0% versus 57.1%, 32.1%, and 10.7% in fluoxetine and desmopressin groups, respectively (p = 0.18). Nighttime arousal was better in the fluoxetine group (41.4%) versus 14.3% in the desmopressin group, p = 0.02, at the first month, and it decreased to 31% in the fluoxetine group versus 14.3% in the desmopressin group, p = 0.13, at the third month. Fluoxetine 20 mg, a selective serotonin reuptake inhibitor, is non-inferior to desmopressin 0.2 mg for the management of PMNE. Fluoxetine improves nighttime arousal significantly at the first month. This improvement becomes insignificant at the third month.
- 1 December 2023
- Published by SAGE Publications in Journal of Endourology
- Vol. 37 (12) , 1305-1313
The Ideal Interval Between Repeated Shockwaves Lithotripsy Sessions for Renal Stones: A Randomized Controlled Trial
Objectives: To assess the ideal interval between repeated shockwaves lithotripsy (SWL) for renal stones. Patient and Methods: Eligible patients with a single renal stone ≤20 mm who required SWL were randomly assigned to one of three groups based on intervals between 1st and 2nd sessions. Patients underwent the 2nd session after 3, 7, and 14 days in groups 1, 2, and 3 respectively. Tubular functions were assessed through comparisons of urinary execration of Kidney Injury Molecule-1 (KIM-1), Neutrophil Gelatinase Associated Lipocalin (NGAL), and Interleukin-18 (IL-18) with pre-SWL values. While glomerular function was assessed by comparisons of protein/creatinine ratio with pre-SWL and changes in ipsilateral renal function on isotope scans. Treatment success was assessed by non-contrast CT after 3 months. Results: All demographics of the 166 patients included in the study were comparable between the three groups. There were significant elevations of tubular biomarkers and protein/creatinine ratio after 1st and 2nd SWL sessions when compared to pre-SWL values (P<0.0001). All tubular biomarkers returned to pre-SWL values at 7 and 14 days after second session while they remained significantly elevated 3 days after second session (P=0.027, <0.001 and <0.001 for KIM-1, NGAL, and IL-18 respectively). SWL success was 73.6% in Group 1, 83.7% in Group 2, and 81% in Group 3. A significant decrease in ipsilateral renal split function was observed in group 1 at the 3-month follow-up. Conclusions: An interval of 7 days is required between SWL sessions when treating renal stones to allow for complete recovery of kidney functions.
- 1 December 2023
- Published by SAGE Publications in Journal of Endourology
- Vol. 37 (12) , 1305-1313
The Ideal Interval Between Repeated Shockwaves Lithotripsy Sessions for Renal Stones: A Randomized Controlled Trial
Objectives: To assess the ideal interval between repeated shockwaves lithotripsy (SWL) for renal stones. Patient and Methods: Eligible patients with a single renal stone ≤20 mm who required SWL were randomly assigned to one of three groups based on intervals between 1st and 2nd sessions. Patients underwent the 2nd session after 3, 7, and 14 days in groups 1, 2, and 3 respectively. Tubular functions were assessed through comparisons of urinary execration of Kidney Injury Molecule-1 (KIM-1), Neutrophil Gelatinase Associated Lipocalin (NGAL), and Interleukin-18 (IL-18) with pre-SWL values. While glomerular function was assessed by comparisons of protein/creatinine ratio with pre-SWL and changes in ipsilateral renal function on isotope scans. Treatment success was assessed by non-contrast CT after 3 months. Results: All demographics of the 166 patients included in the study were comparable between the three groups. There were significant elevations of tubular biomarkers and protein/creatinine ratio after 1st and 2nd SWL sessions when compared to pre-SWL values (P<0.0001). All tubular biomarkers returned to pre-SWL values at 7 and 14 days after second session while they remained significantly elevated 3 days after second session (P=0.027, <0.001 and <0.001 for KIM-1, NGAL, and IL-18 respectively). SWL success was 73.6% in Group 1, 83.7% in Group 2, and 81% in Group 3. A significant decrease in ipsilateral renal split function was observed in group 1 at the 3-month follow-up. Conclusions: An interval of 7 days is required between SWL sessions when treating renal stones to allow for complete recovery of kidney functions.
- Open Access
- 24 September 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 56 (2) , 399-405
Randomized trial to assess the potential role of ascorbic acid and statin for post-contrast acute kidney injury prevention
Purpose: To evaluate the effect of using statins and ascorbic acid for the prevention of post-contrast acute kidney injury (PC-AKI) in patients undergoing urologic diagnostic elective contrast-enhanced computed tomography (CECT). Methods: This registered trial (NCT03391830) was for statin naïve patients underwent elective CECT. Patients were randomized allocated to two groups: the first group received atorvastatin 80-mg the day before the study and atorvastatin 40-mg two hours before the CECT and for continue on atorvastatin 40-mg two days after CECT; plus ascorbic acid 500 mg with atorvastatin. The other group received two tablets of placebo once/daily before the procedure and for another 3 days. The primary outcome was to assess the incidence PC-AKI. Results: The baseline parameters were comparable between both groups. The final median (interquartile range “IQR”) serum creatinine were 0.80 (0.60, 1.00) and 0.80 (0.60, 1.00), respectively, with insignificant p-value (p = 0.8). The median (IQR) final estimated GFR were 95.2 (72.8, 108.1) and 88.6 (71.9, 111.0) mL/min in placebo and statin plus ascorbic acid groups, respectively (p = 0.48). The eGFR difference median (IQR) were − 6.46 (− 11.72, − 4.18) and − 6.57 (− 13.38, − 3.82) ml/min in placebo and statin plus ascorbic acid groups, respectively (p = 0.58). PC-AKI occurred in 11 patients (9.8%) in placebo group and in 3 patients (3%) in statin plus ascorbic acid group (p = 0.04). Conclusions: Statin and ascorbic acid did not statistically improve neither serum creatinine nor eGFR values in patient underwent CECT. However, it can decrease the incidence of the clinically insignificant PC-AKI.
- 24 September 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 56 (2) , 399-405
Open AccessRandomized trial to assess the potential role of ascorbic acid and statin for post-contrast acute kidney injury prevention
Purpose: To evaluate the effect of using statins and ascorbic acid for the prevention of post-contrast acute kidney injury (PC-AKI) in patients undergoing urologic diagnostic elective contrast-enhanced computed tomography (CECT). Methods: This registered trial (NCT03391830) was for statin naïve patients underwent elective CECT. Patients were randomized allocated to two groups: the first group received atorvastatin 80-mg the day before the study and atorvastatin 40-mg two hours before the CECT and for continue on atorvastatin 40-mg two days after CECT; plus ascorbic acid 500 mg with atorvastatin. The other group received two tablets of placebo once/daily before the procedure and for another 3 days. The primary outcome was to assess the incidence PC-AKI. Results: The baseline parameters were comparable between both groups. The final median (interquartile range “IQR”) serum creatinine were 0.80 (0.60, 1.00) and 0.80 (0.60, 1.00), respectively, with insignificant p-value (p = 0.8). The median (IQR) final estimated GFR were 95.2 (72.8, 108.1) and 88.6 (71.9, 111.0) mL/min in placebo and statin plus ascorbic acid groups, respectively (p = 0.48). The eGFR difference median (IQR) were − 6.46 (− 11.72, − 4.18) and − 6.57 (− 13.38, − 3.82) ml/min in placebo and statin plus ascorbic acid groups, respectively (p = 0.58). PC-AKI occurred in 11 patients (9.8%) in placebo group and in 3 patients (3%) in statin plus ascorbic acid group (p = 0.04). Conclusions: Statin and ascorbic acid did not statistically improve neither serum creatinine nor eGFR values in patient underwent CECT. However, it can decrease the incidence of the clinically insignificant PC-AKI.
- 13 July 2023
- Published by Wiley in BJU International
- Vol. 132 (4) , 404-410
The effect of piezoelectric shockwave lithotripsy with 2‐ and 8‐mm focus sizes on stone disintegration and renal injury
Objectives: To compare the efficacy and safety of shockwave lithotripsy (SWL) using a narrow focus or wide focus for renal stones. Patients and Methods: A double‐blind randomised trial included adult patients with a solitary radio‐opaque renal pelvic stone of 1–2 cm. Patients were randomised into two groups: narrow‐focus (2 mm) SWL and wide‐focus (8 mm) SWL. The stone‐free rate (SFR) and presence of complications such as haematuria, fever, pain, and peri‐renal haematoma were evaluated. Pre‐ and postoperative urinary markers (neutrophil gelatinase‐associated lipocalin [NGAL] and kidney injury molecule 1 [KIM‐1]) concentrations were compared to assess renal injury. Results: A total of 135 patients were recruited for this study. The SFR after the first SWL session was 79.2% and 69.1% in narrow‐ and wide‐focus groups, respectively. There was a comparable rise in the median 2‐h NGAL concentration in both groups ( P = 0.62). However, the rise in the median (interquartile range [IQR]) 2‐h KIM‐1 concentration was significantly higher in the narrow‐focus group at 4.9 (4.6, 5.8) ng/mL compared with the wide‐focus group at 4.4 (3.2, 5.7) ng/mL ( P = 0.02). Nevertheless, the 3‐day NGAL and KIM‐1 urinary marker concentrations were significantly improved ( P = 0.263 and P = 0.963, respectively). The overall SFR after three sessions was 86.6% and 86.8% in the narrow‐ and wide‐focus groups, respectively ( P = 0.77). Both groups were comparable for complications, apart from the median pain score and the percentage of high‐grade haematuria, which were significantly higher in the narrow‐focus group ( P < 0.001 and P = 0.03, respectively). Conclusion: Narrow‐ and wide‐focus SWL were associated with comparable outcomes and re‐treatment rates. However, narrow‐focus SWL was associated with significantly higher morbidity in terms of pain and haematuria.
- 13 July 2023
- Published by Wiley in BJU International
- Vol. 132 (4) , 404-410
The effect of piezoelectric shockwave lithotripsy with 2‐ and 8‐mm focus sizes on stone disintegration and renal injury
Objectives: To compare the efficacy and safety of shockwave lithotripsy (SWL) using a narrow focus or wide focus for renal stones. Patients and Methods: A double‐blind randomised trial included adult patients with a solitary radio‐opaque renal pelvic stone of 1–2 cm. Patients were randomised into two groups: narrow‐focus (2 mm) SWL and wide‐focus (8 mm) SWL. The stone‐free rate (SFR) and presence of complications such as haematuria, fever, pain, and peri‐renal haematoma were evaluated. Pre‐ and postoperative urinary markers (neutrophil gelatinase‐associated lipocalin [NGAL] and kidney injury molecule 1 [KIM‐1]) concentrations were compared to assess renal injury. Results: A total of 135 patients were recruited for this study. The SFR after the first SWL session was 79.2% and 69.1% in narrow‐ and wide‐focus groups, respectively. There was a comparable rise in the median 2‐h NGAL concentration in both groups ( P = 0.62). However, the rise in the median (interquartile range [IQR]) 2‐h KIM‐1 concentration was significantly higher in the narrow‐focus group at 4.9 (4.6, 5.8) ng/mL compared with the wide‐focus group at 4.4 (3.2, 5.7) ng/mL ( P = 0.02). Nevertheless, the 3‐day NGAL and KIM‐1 urinary marker concentrations were significantly improved ( P = 0.263 and P = 0.963, respectively). The overall SFR after three sessions was 86.6% and 86.8% in the narrow‐ and wide‐focus groups, respectively ( P = 0.77). Both groups were comparable for complications, apart from the median pain score and the percentage of high‐grade haematuria, which were significantly higher in the narrow‐focus group ( P < 0.001 and P = 0.03, respectively). Conclusion: Narrow‐ and wide‐focus SWL were associated with comparable outcomes and re‐treatment rates. However, narrow‐focus SWL was associated with significantly higher morbidity in terms of pain and haematuria.
- Open Access
- 6 March 2023
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 35 (1) , 1-5
Impact of changing PI-RADS cutoff on prostate cancer detection by MRI cognitive fusion biopsy in biopsy-naïve patients
Background: Multi-parametric magnetic resonance imaging may improve the detection of prostate cancer. The aim of this work is to compare between PI-RADS 3–5 and PI-RADS 4–5 as a threshold for targeted prostatic biopsy. Methods: This is a prospective clinical study that included 40 biopsy-naïve patients referred for prostate biopsy. Patients underwent prebiopsy multi-parametric (mp-MRI), followed by 12-core transrectal ultrasound-guided systematic biopsy and cognitive MRI/TRUS fusion targeted biopsy from each detected lesion. The primary endpoint was to assess the diagnostic accuracy of the PI-RAD 3–4 versus PI-RADS 4–5 lesion by mpMRI for prostate cancer detection in biopsy-naive men. Results: The overall prostate cancer detection rate and the clinically significant cancer detection rate were 42.5% and 35%, respectively. Targeted biopsies from PI-RADS 3–5 lesions showed a sensitivity of 100%, specificity of 44%, positive predictive value of 51.7%, and negative predictive value of 100%. Restricting targeted biopsies to PI-RADS 4–5 lesions resulted in a decrease in sensitivity and negative predictive value to 73.3% and 86.2%, respectively, while specificity and positive predictive value were increased to 100% for both parameters which was statistically significant (P value < 0.0001 and P value = 0.004, respectively). Conclusions: Limiting the TBs to PI-RADS 4–5 lesions improves the performance of mp-MRI in the detection of prostate cancer especially aggressive tumors.
- 6 March 2023
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 35 (1) , 1-5
Open AccessImpact of changing PI-RADS cutoff on prostate cancer detection by MRI cognitive fusion biopsy in biopsy-naïve patients
Background: Multi-parametric magnetic resonance imaging may improve the detection of prostate cancer. The aim of this work is to compare between PI-RADS 3–5 and PI-RADS 4–5 as a threshold for targeted prostatic biopsy. Methods: This is a prospective clinical study that included 40 biopsy-naïve patients referred for prostate biopsy. Patients underwent prebiopsy multi-parametric (mp-MRI), followed by 12-core transrectal ultrasound-guided systematic biopsy and cognitive MRI/TRUS fusion targeted biopsy from each detected lesion. The primary endpoint was to assess the diagnostic accuracy of the PI-RAD 3–4 versus PI-RADS 4–5 lesion by mpMRI for prostate cancer detection in biopsy-naive men. Results: The overall prostate cancer detection rate and the clinically significant cancer detection rate were 42.5% and 35%, respectively. Targeted biopsies from PI-RADS 3–5 lesions showed a sensitivity of 100%, specificity of 44%, positive predictive value of 51.7%, and negative predictive value of 100%. Restricting targeted biopsies to PI-RADS 4–5 lesions resulted in a decrease in sensitivity and negative predictive value to 73.3% and 86.2%, respectively, while specificity and positive predictive value were increased to 100% for both parameters which was statistically significant (P value < 0.0001 and P value = 0.004, respectively). Conclusions: Limiting the TBs to PI-RADS 4–5 lesions improves the performance of mp-MRI in the detection of prostate cancer especially aggressive tumors.
- 1 November 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (5) , 1133-1134
Reply by Authors
- 1 November 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (5) , 1133-1134
Reply by Authors